Clinical Trials Market OverviewThe Clinical Trials Market report delivers crucial insights into the market's growth ...

Is IDEXX Laboratories a good investment? Analyzing its consistent growth, innovative products, and international expansion ...

Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term. Read why MEDP stock is a Strong Buy.

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Q4 2024 Earnings Call Transcript February 4, 2025 Dassault Systèmes SE beats earnings expectations. Reported EPS is $0.43, ...

However, Amgen’s forward revenue guidance may also be behind the stock’s post-earnings slide. The company expects revenue to ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

AI’s role in healthcare evolved significantly in 2024. Rather than generic AI solutions, startups focused on specialized, ...